| Company Name: |
J & K SCIENTIFIC LTD.
|
| Tel: |
010-82848833 400-666-7788 |
| Email: |
jkinfo@jkchemical.com |
| Products Intro: |
Product Name:Avosentan
CAS:290815-26-8
Package:100Mg,10Mg
|
|
| | avosentan Basic information |
| Product Name: | avosentan | | Synonyms: | N-(6-Methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)-pyrimidin-4-yl)-5-methylpyridine-2-sulfonamide;N-(6-Methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)-pyrimidin-4-yl)-5-methylpyridine-2-sulfonam;2-Pyridinesulfonamide,N-[6-methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]-5-methyl-;avosentan;N-[6-Methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]-5-methyl-2-pyridinesulfonamide;Ro 67-0565;SPP-301;Avosentan (SPP301) | | CAS: | 290815-26-8 | | MF: | C23H21N5O5S | | MW: | 479.51 | | EINECS: | | | Product Categories: | | | Mol File: | 290815-26-8.mol |  |
| | avosentan Chemical Properties |
| Boiling point | 575.5±60.0 °C(Predicted) | | density | 1.363 | | storage temp. | Store at -20°C | | solubility | DMSO : 6.67 mg/mL (13.91 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) | | form | Powder | | pka | 3.19±0.10(Predicted) |
| | avosentan Usage And Synthesis |
| Uses | Avosentan is a competitive antagonist of Endothelin-1 (ET-1) with a high selectivity for the ETA receptor. Avosentan may be a potential option in the treatment of glaucoma. | | Enzyme inhibitor | This potent, selective and orally available endothelin A receptor blocker (FW = 479.51 g/mol; CAS 290815-26-8; Soluble in DMSO), also known by its code names SPP301 and Ro 67-0565, induces the dose-dependent reduction in the fractional renal excretion of sodium (up to 8.7% at 50 mg avosentan), with a paralleled dose-related increase in proximal sodium reabsorption. Avosentan reduces albuminuria, when added to standard treatment in patients with type 2 diabetes and overt nephropathy, but induces significant fluid overload and congestive heart failure. |
| | avosentan Preparation Products And Raw materials |
|